Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

HER1/EGFR targeting: refining the strategy.

Román Pérez-Soler1

  • 1Department of Oncology, Montefiore Medical Center/Albert Einstein College of Medicine, Bronx, New York 10467, USA. rperezso@montefiore.org

The Oncologist
|February 3, 2004
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Editor's Note: HHLA2, a New Immune Checkpoint Member of the B7 Family, Is Widely Expressed in Human Lung Cancer and Associated with EGFR Mutational Status.

Clinical cancer research : an official journal of the American Association for Cancer Research·2025
Same author

Seroconversion rates following COVID-19 vaccination among patients with cancer.

Cancer cell·2021
Same author

First-in-human study of inhaled Azacitidine in patients with advanced non-small cell lung cancer.

Lung cancer (Amsterdam, Netherlands)·2021
Same author

Impact and Diagnostic Gaps of Comprehensive Genomic Profiling in Real-World Clinical Practice.

Cancers·2020
Same author

Case Fatality Rate of Cancer Patients with COVID-19 in a New York Hospital System.

Cancer discovery·2020
Same author

Survival Disparities in Black Patients With EGFR-mutated Non-small-cell Lung Cancer.

Clinical lung cancer·2019
Same journal

Target trial emulation studies in oncology: a comprehensive analysis.

The oncologist·2026
Same journal

Durable Response to Sotorasib in KRAS G12C-Mutant Intrahepatic Cholangiocarcinoma: A Case Report.

The oncologist·2026
Same journal

The Impact of Relative Dose Intensity on pCR in Neoadjuvant Chemotherapy of Muscle-Invasive Urothelial Cancer: a Multicentre Retrospective Study.

The oncologist·2026
Same journal

Prevalence, treatment and survival of Malignant Peripheral Nerve Sheath Tumor in the Danish neurofibromatosis type 1 population.

The oncologist·2026
Same journal

Molecular Tumor Board-Guided Osimertinib Therapy in EGFR L858R/Q701L-Mutant Lung Adenocarcinoma Supported by Functional Validation.

The oncologist·2026
Same journal

Phase 2 Dose Expansion Trial of OBI-3424, a DNA-Alkylating Prodrug, in Patients with Advanced Solid Tumors Expressing AKR1C3.

The oncologist·2026
See all related articles

Targeting human epidermal growth factor receptor (EGFR) offers therapeutic potential, but complex signaling requires further research. Optimizing intracellular HER therapies, like tyrosine kinase inhibitors, needs more clinical experience and patient selection.

Area of Science:

  • Oncology
  • Molecular Biology
  • Pharmacology

Background:

  • Human epidermal growth factor receptor (EGFR) and HER family signaling pathways are crucial in tumor growth, proliferation, survival, and metastasis.
  • Understanding the complex intracellular and extracellular signaling mechanisms of HER receptors is essential for effective cancer therapy.
  • Targeting HER receptors represents a significant area of drug development for various cancers, including non-small cell lung cancer (NSCLC).

Purpose of the Study:

  • To clarify the complex biology of HER receptor signaling.
  • To discuss the therapeutic targets within the HER signaling system.
  • To evaluate the clinical development and potential of HER-targeting agents, including tyrosine kinase inhibitors and monoclonal antibodies.

Main Methods:

Related Experiment Videos

  • Review of current understanding of HER family receptor biology and signaling pathways.
  • Analysis of therapeutic strategies targeting HER receptors, including extracellular and intracellular approaches.
  • Examination of clinical trial outcomes, particularly for gefitinib in NSCLC, and factors influencing results.

Main Results:

  • HER family signaling pathways are intricate, involving multiple receptors and activation mechanisms that drive tumor progression.
  • Both extracellular (monoclonal antibodies) and intracellular (tyrosine kinase inhibitors) agents are advanced in clinical development.
  • Disappointing Phase III trial results for gefitinib in NSCLC highlight the need for careful patient selection, dosing, and trial design.

Conclusions:

  • Intracellular targeting of HER receptors is a novel approach with potential, but requires further optimization.
  • Clinical experience with HER-targeting agents is still evolving, and more data is needed to fully understand their efficacy.
  • Factors such as patient characteristics and trial design significantly impact the outcomes of HER-targeted therapies in NSCLC.